Impact of Ga68-DOTATOC PET/MRI on Therapy Management in Patients with Neuroendocrine Neoplasia (NEN) - Preliminary Results Abstract #2882

Introduction: Integrated PET/MRI combines the sensitivity and functional relevance of PET imaging and the spatial resolution and soft tissue contrast of MRI.
Aim(s): To evaluate the influence of the submodalities of 68Ga-DOTATOC PET/MRI on therapeutic strategy in patients with known or suspected neuroendocrine neoplasms (NEN).
Materials and methods: 80 patients with histologically confirmed (68) or suspected (12) NEN (34 f; age 66 [29-82] y) received PET/MRI between February 2017 and April 2019. PET and contrast enhanced MRI were separately evaluated in consensus by two independent blinded readers. Results were presented during simulated tumor boards, and the respective strategy was compared with the original decision based on hybrid PET/MRI made by the institutional tumor board. Impact of submodalities was tested with the McNemar test.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Piotr Radojewski

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2831 Immunohistochemical Profile of Digestive Neuroendocrine Neoplasms: A Retrospective Analysis in a Single Algerian Institution
Introduction: Neuroendocrine Noplasms (NEN) are rare tumours, but their incidence is clearly increasing in our country due to the improvement of diagnostic means, in particular the generalization of immunohistochemical techniques. The digestive location represents more than 70% of the cases. The anatomopathological study enables to classify the NEN in different prognostic grades according to the degree of differentiation, mitotic index and Ki67.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Djihed Belabdi
#2916 Pretherapeutic Heterogeneity of Somatostatin Receptor Expression in Neuroendocrine Neoplasia: An Innovative Predictor of Response to Everolimus?
Introduction: In patients with bronchopulmonary or gastroenteropancreatic neuroendocrine neoplasms (NEN) the mTOR inhibitor everolimus may prolong progression-free survival (PFS). However, this is countered by potentially significant toxicity.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr. med. Christoph Wetz
Authors: Wetz C, Genseke P, Schatka I, Jann H, ...
#2952 Genomic Landscape of Neuroendocrine Neoplasms from Gastrointestinal Tract, Pancreas, Lung, Rare and Unknown Primary Locations
Introduction: There are still few large-scale sequencing data to depict the genomic landscape of neuroendocrine neoplasms (NEN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Professor Jie Chen
Authors: Chen L, Liu M, Zhang Y, Guo Y, ...
#2950 Hemicolectomy for Neuroendocrine Neoplasms of the Appendix - Is It Really Necessary?
Introduction: Appendical neuroendocrine neoplasms (ANENs) are rare. Limited data is available regarding prognosis and optimal treatment strategy in those tumors
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Orit Twito
Authors: Twito O, Klein N, Paran H, Avital S, ...
#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board
Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Fabrice Viol
Authors: Viol F, Sipos B, Amin T, Fahl M, ...